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Non-communicable diseases (NCDs) kill more than 41 million people every year, accounting for 71% of all
deaths globally. The prevalence of NCDs is estimated to be higher than that of infectious diseases in Africa by
2030. Precision medicine may help with early identification of cases, resulting in timely prevention and
improvement in the efficacy of treatments. However, Africa has been lagging behind in genetic research, a
key component of the precision medicine initiative. A number of genomic research initiatives which could
lead to translational genomics are emerging on the African continent which includes the Non-communicable
Diseases Genetic Heritage Study (NCDGHS) and the Men of African Descent and Carcinoma of the Prostate
(MADCaP) Network. These offer a promise that precision medicine can be applied in African countries. This
review evaluates the advances of genetic studies for cancer, hypertension, type 2 diabetes and body mass
index (BMI) in Africa.
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Non-communicable diseases (NCDs) are the leading cause of
global mortality, accounting for 71% of all deaths [1,2]. Notably, 80%
of these NCD deaths are from four diseases, type 2 diabetes (T2D),
cancer, respiratory diseases and cardiovascular disease, that annually
have mortality rates of 1.6, 9.0, 3.9 and 17.9 million respectively [2].
Africa is experiencing a double burden of infectious diseases and
NCDs. However, by 2030, deaths from NCDs in Africa are projected to
exceed deaths due to communicable, maternal, perinatal and nutri-
tional diseases combined [1]. Furthermore, it is estimated that more
than 70% of the global mortality of cancers will occur in Africa withinthe next decade [3]. Urgent strategies are required to curb this NCD
pandemic.
Strategies for preventing and controlling NCDs, such as hyperten-
sion and diabetes, are being implemented in Africa and integrated
into HIV initiatives, given the double burden of infectious diseases
and these NCDs [4]. These population-wide interventions include
mass communication for promoting healthy lifestyles, through
increased consumption of fruits and vegetables and physical activity
[2,4]. However, the current treatment and preventative interventions
are based on a “one size fits all” approach [5]. People respond differ-
ently to these interventions and some even experience unfavorable
reactions. Precision medicine offers the hope that the right person
will get the right treatment and help reduce adverse treatment reac-
tions [5]. Through this approach high-risk individuals may be identi-
fied early and provided with requisite preventative and therapeutic
options.
There are many ‘Omics’ technologies, including proteomics, geno-
mics, and metabolomics, that are key to enhancing precision medi-
cine [6]. However, for this review, we will focus on genomics. NCDs
are heritable and extensive studies to unravel the genetic factors
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lations [7]. However, due to the genetic diversity within Africa and
differences in linkage disequilibrium patterns between Europeans
and Africans, the generalizability of these findings is limited [7]. The
summation of genetic variants into polygenic risks scores seems
promising to enable precision medicine efforts through stratification
of individuals according to their genetic risk. However, the low repre-
sentation of Africans in genome-wide association studies (GWAS)
was noted to result in a 4.9-fold reduction in predictivity for 17 quan-
titative traits that include BMI in Africans compared to Europeans [8].
A number of initiatives such as the United Kingdom Biobank (UKBB)
and Million Veteran programs are enhancing diversity to capture the
genetic variation present in other populations and ethnic groups.
Notably, the UKBB and MVP consist of 8000 and approximately
60,000 Africans respectively [9,10]. Nonetheless these are
admixed Africans. Other ethnic groups, such as Europeans, are
now reaching the point where millions of individual genomes are
available for GWAS[11]. Such underrepresentation might lead to
the exacerbation of health disparities[8]. Recently, a whole
genome study of 426 continental Africans, representing 50 ethno-
linguistic groups, reported great genetic diversity in continental
Africans. From this, three million novel variants were discovered
after comparing with thousands of other African genomes in pub-
lic databases[12]. By relying on genetics of Africans in the dias-
pora, novel genetic variants associated with NCDs in continental
Africans will be missed. Therefore, the representation of conti-
nental Africans needs to be prioritized.
This review will evaluate the advances that have been made
on the African continent for genetic studies of NCDs, using cancer,
diabetes, hypertension and obesity as examples. We will evaluate
what has transpired in this field of study from 2009 to 2019, in
Africa.
2. The progress of genetics studies for NCDs on the African
continent
Early genetic studies were primarily performed in a few South
African and Tunisian labs and were led by small research groups.
Advances in technology subsequently led to genome-wide associ-
ation studies (GWAS) studies which spurred population genetics
approaches in larger GWAS consortia and led to the design of
Afrocentric genotyping arrays. These above-mentioned aspects
are described in detail, in the following sections and illustrated in
Fig. 1.Fig. 1. Schematic outline of the progress, development and support of genetics research in
about 99,408 participants, African Partnerships of Chronic Disease Research (APCDR) has 7
GHS) is planning to recruit 100,000 participants. The South African Human Genome Project (2.1. Candidate Gene studies
Due to limited capacity and resources, candidate gene studies
were commonly used for evaluating the genetics of NCDs in South
Africa and Tunisia (Fig. 2). These studies were targeted on particular
genetic sites of interest and thus a limited number of SNPs, ranging
from one to 250, in smaller studies of hundreds of participants were
evaluated. Notably, some key genetic factors were associated with
breast, cervical, oesophageal and prostate cancer which are the most
common cancers in Africa [13-15]. Moreover, the rs12255372 variant
of TCF7L2 was also associated with obesity in Cameroonians [16]. The
majority of these early studies used genetic variants associated with
NCDs in European and Asian populations that were limited by the dif-
ferences in allele frequencies and LD pattern in Africans.
As a consequence of the sparse genetic data in continental Afri-
cans, African American participants were used for replication efforts.
For instance, the association of the rs1121980 and rs7204609 var-
iants of the FTO gene with BMI in West Africans were replicated in
African Americans [17]. The implication of this limitation was the
inability to properly explore the genetic diversity of Africans.
Although candidate studies are still being conducted for cancer, this
approach has been criticized for poor replication even in Europeans
and is thought to be biased by our incomplete understanding of gene
functions[18]. These are some of the challenges that led to the quest
for hypothesis free approaches such as GWAS for evaluating the
genetic determinants of complex traits [19].
2.2. GWAS of NCDs in Africa
With the gradual advancement of GWAS in Africa, the utilization
of genotyping arrays, such as the Metabochip, enabled the evaluation
of the associations of about 200,000 genetic variants with NCDs [20].
Although, the Metabochip was a targeted candidate gene based array
that lacked full genome-wide coverage, its use in evaluating genetic
associations for BMI and hypertension led to notable results in Afri-
cans [21-23]. Some of these include the association of SEC16B variants
with BMI in black South Africans which had not been identified in
previous candidate gene studies (Table 1) [22]. The Affymetrix geno-
typing array, comprised of about two million SNPs, helped to provide
some insights of the genetic determinants of NCDs in Africa. Through
this genotyping array a novel gene, SEMA4D, was found to be associ-
ated with BMI in West Africans [24]. Other novel genes such as
ZRANB3 were found to be uniquely associated with T2D in continen-
tal Africans [25]. However, most GWAS genotyping arrays wereAfrica. Human Hereditary and Health in Africa (H3Africa) is ongoing and has recruited
000 participants, and the Non-communicable Diseases Genetic Heritage Study (NCD-
SAHGP) was funded by the government of South Africa.
Fig. 2. Number of candidate genetic studies of selected NCDs that have been conducted in African countries from 2009 to 2019.DRC, Democratic Republic of Congo.
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T2D = type 2 diabetes, BMI = body mass index, ARIC = Atherosclerosis Risk in Communities study, CFS = Cleveland Family Study, HUFS = Howard University Family Study, Jackson
Heart Study = JHS, MESA = Multi-Ethnic Study of Atherosclerosis, DDS = Durban Diabetes Study, DCC = Durban Case Control Study, UGR = Uganda Genome Resource
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Table 2
Consortia for NCDs and genetics in Africa.
Name of Consortia Aims and Objectives Target Sample sizes African countries covered
Human Hereditary and
Health in Africa (H3Africa)
https://h3africa.org/
To create and support a pan-continental net-
work of laboratories that will be equipped
to apply leading-edge research to the study
of the complex interplay between environ-
mental and genetic factors which deter-
mines disease susceptibility and drug
responses in African populations.
99,408 30 countries located in the North, South East,





To assess the burden, spectrum and genetic
determinants of various cardio-metabolic






It was an international network of research
groups which worked together to facilitate
and promote collaborative research of
chronic diseases across Africa.
7000 Uganda




To assess genomic susceptibility to carci-
noma of the prostate in African descent
populations.
576, recruitment ongoing Ghana, Senegal, Nigeria, Mauritius, South
Africa
Evolving Risk Factors





To identify genetic variants associated with
breast, cervical and oesophageal cancer.





To coordinate etiologic and molecular studies
of esophageal cancer in high-risk popula-
tions within Africa.
12,000 Ethiopia, Kenya, Tanzania, Malawi, Zambia,
South Africa
4 T. Chikowore et al. / EBioMedicine 65 (2021) 103260designed based on the genetic variation of European populations and
therefore, might have missed the population-specific variants associ-
ated with NCDs in African populations [26].
Despite the improved efficacy to discover more genetic variants
associated with NCDs through GWAS in African populations, most
studies were underpowered to adequately detect significant associa-
tions [17]. Notably, only two GWASs have investigated the genetic
variants associated with cancer in Africa [27,28]. These GWASs were
performed in Tunisian and Ghanaian men with prostate cancer. In
Tunisia, 14 SNPs located in 9p24, 17q21 and 22q13 were identified as
associated with prostate cancer [27]. This study included 90 prostate
cancer cases and 131 controls in the discovery stage and 155 prostate
cancer cases and 182 controls in the replication stage. However, this
small scale GWAS failed to replicate 14 SNPs in Qatari and Saudi Ara-
bian men with prostate cancer [27]. Another small scale GWAS of
474 prostate cancer cases and 458 healthy controls in Ghana identi-
fied rs34575154, rs985081 and rs2185710 to be associated with high
Gleason score prostate cancer [28]. However, these SNPs were not
successfully replicated in 5,096 African Americans men with prostate
cancer. There are currently ongoing GWASs across Africa aiming to
identify genetic variants associated with cancer through various
research groups and consortia including Evolving Risk Factors for
Cancers in African Populations (ERICA), African Female Breast Cancer
Epidemiology (AFBRECANE), and Africa Esophageal Cancer Consor-
tium (AfrECC). For a summary of relevant consortia, see Table 2. A
map showing the study sites of respective NCD and genetic consortia
in Africa is presented in Fig. 3. Due to the efforts of these consortia
there is great hope that the next frontier of genetic discoveries will
be in Africa.
2.3. Consortium wide genetic studies
Through the funding of the Wellcome Trust and United States
National Institutes of Health (NIH), a great boost to the study of the
genetics in Africa was ignited in 2010 when the H3Africa consortiumwas developed [29]. These funds have led to the establishment of Bio-
banks, capacity development program initiatives, mentoring oppor-
tunities for early-career academics, and the establishment of multi-
country collaborative studies. Combined, these efforts have signifi-
cantly improved research output and scope on the African continent.
H3Africa has networks and working groups such as the H3Africa Bio-
informatics Network (H3ABioNet) and the Cardiovascular H3Africa
Innovation Resource (CHAIR). Notably, through the efforts of the
H3Africa Bioinformatics Network (H3ABioNet) a robust Afrocentric
genotyping array was developed using 350 whole genome sequences
from H3Africa, Wellcome Sanger and 1000Genomes reference panels
to enhance the coverage of more population-specific variants [30].
CHAIR is a key partnership of H3Africa projects which among its
objectives seeks to explore the genetic determinants of NCDs in
Africa. CHAIR is working towards overcoming the limitations of
smaller sample sizes in GWAS, by harmonizing the genetic and phe-
notype datasets of H3Africa projects to enhance the discovery of
novel associations for cardiometabolic traits [31].
Early cohorts from Uganda, West Africa and South Africa were
also combined recently under the African Partnership of Chronic
Disease Research (APCDR) Network resulting in a landmark paper
exploring 34 cardiometabolic traits [32]. This laid a foundation
that will be leveraged by other H3Africa studies in further explor-
ing the genetics of NCDs [32]. In this paper, improvements in the
imputation accuracy of the 1000 genomes version 3 reference
panel of Africans were noted when it was combined with whole
genome sequences from Uganda and the African Variation
Genome Programme (AVGP). Notably the number of successfully
imputed variants (info score > 0.3) increased by 1.5 million in
East African populations and 8 million in Baganda [32]. This
shows the importance of having a diverse reference panel of Afri-
cans for imputation efforts in Africa. Two novel signals for BMI
were discovered through the meta-analysis of the APCDR, Amer-
ica Diabetes Mellitus (AADM) study, Durban Diabetes (DDS) study
and Durban Case Control study (DCC)[32]. Moreover, a
Fig. 3. NCDs and genetics consortia coverage in Africa. The Human Hereditary and Health in Africa (H3Africa), is the largest and widest consortium in Africa, to date (over 30 African
countries). Non-communicable Diseases Genetic Heritage Study (NCD-GHS) is based in Nigeria. The African Partnerships of Chronic Disease Research (APCDR) is in Uganda, the
Evolving Risk Factors for Cancers in African Populations (ERICA-SA) is underway in South Africa, the Africa Esophageal Cancer Consortium (AfrECC) is underway in six countries,
and the Men of African Descent and Carcinoma of the Prostate (MADCaP) recruitment is underway in four countries. The consortia coverage above is based on the study sites of the
respective consortia.
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eastern coast of Africa from Ethiopia to South Africa, known as
the Africa’s Oesophageal Cancer Corridor, is conducting the larg-
est GWAS of esophageal cancer in the continent (Fig. 3) [33]. This
project is funded by the NIH and aims to unravel key genetic fac-
tors and biological pathways involved in the pathogenesis of
esophageal cancer in Africa, thereby providing a platform for risk
prediction and precision medicine.
Attempts are now being made to evaluate genetic susceptibly
using polygenic risk scores (PRS) for cancer in the Men of African
Descent and Carcinoma of the Prostate (MADCaP) Network. Over
and above the H3Africa array, this network has designed a geno-
typing array to aid the identification of Afrocentric variants for
cancer and to explore polygenic risk scores [34]. An earlier study
of a genetic risk score containing 100 European derived genetic
variants found that the top 10% of Ugandan men had a 4.86-fold
(95%CI:2.70, 8.76) increase in prostate cancer risk [35]. However,
through the evidence from the MADCaP network, the heterogene-
ity of PRS prediction within continental Africans was depicted
[34], implying findings from Uganda may not be applied to other
African countries. Thus, more efforts are required to evaluate the
possible heterogeneity of PRS prediction within the continent.
The limited clinical utility of polygenic risk scores due to low dis-
criminative ability has been reported even in Europeans [36,37].
Therefore, novel approaches to enhance PRS prediction are
required.2.4. Industry and government partnerships
Aside from the scientific community, some African governments
are now seeing the value of genetic studies. Notably, the South Afri-
can government supported a landmark initiative for sequencing the
genomes of indigenous and local Africans through the South Africa
Genome Project (SAHGP) [29]. These genetic resources, in addition to
others in the African continent, were pivotal in the development of
the African genotyping array and will be instrumental for future pre-
cision medicine efforts. The potential value of the genetics of Africans
in leading to the development of novel therapies has also attracted
the attention of African industry partners. Notably, the blockbuster
PCSK9 inhibitors were developed to mimic the effects of the choles-
terol lowering PCSK9 variants that are more prevalent in individuals
of African ancestry [38-40]. The NCD-GHS study is a unique ground-
breaking initiative, which will also help enhance precision medicine
efforts in Africa by establishing a genetic resource for studying NCDs
in 100,000 participants (Fig. 1). There is hope that more similar part-
nerships may increase as industries gradually become involved in
collaborative efforts with academic institutions to translate findings
for clinical application.
3. Outstanding questions
Although the establishment of different consortia are a crucial
development on the continent, there remain some key questions and
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these include: Are the genetic determinants of the NCDs the same in
continental Africans? How efficient are the current methods of poly-
genic risk scores predictions for African populations? The current
databases such as FUMA, GTEX [41], etc. that are used to determine
the functional role of the identified genetic variants are improving
the representation of African Americans through initiatives such as
TOPMed (Trans-Omics for Precision Medicine) . However since Afri-
can Americans are admixed and greater genetic diversity exists in
continental Africans, there is a need to include/create an Afrocentric
database such as the African Functional Genomics Resource (AFGR)
[42] of variants which might not be in these databases but are signifi-
cantly associated with NCDs in continental Africans[12]. Further-
more, elucidation of causality and related studies such as Mendelian
randomization and randomized clinical trials will be required in the
future to give robust evidence that may help in the application of
these findings in precision medicine. We also acknowledge that
multi-omics approaches are required to enhance the realization of
precision medicine in Africa. There is a growing number of micro-
biome studies for obesity and diabetes in the African continent which
will also be informative in this regard
4. Conclusion
Africa is a continent with great genetic diversity that promises to
be beneficial in the global elucidation of the pathogenesis of NCDs.
There has, however, been a lag in the utilization of these unique
genetic resources to facilitate the implementation of precision medi-
cine on the continent. However, this is understandable as not many
robust signals of association for NCDs have been documented. Never-
theless, a solid foundation to facilitate efforts towards the discovery
of novel genetic advances has been set by funding bodies through
platforms like the H3Africa as well as industry and academic partner-
ships such as the recently launched NCD-GHS study. There is great
anticipation that Africa is well on its way to employ precision medi-
cine in the efforts to curb the raging NCDs pandemic.
5. Search strategy
We used the keywords Africa, genetics, blood pressure/hyperten-
sion, cancer, diabetes, BMI, obesity to select the papers in the PubMed
database from 2009 to 2019.
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